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AbstrACt
Introduction It is challenging to obtain a reliable bleeding 
history in children who are referred for a suspected 
inherited bleeding disorder. Bleeding symptoms may be 
subtle as children face fewer haemostatic challenges 
compared with adults. In order to standardise bleeding 
histories, questionnaires have been developed, called 
bleeding assessment tools (BATs). Although it has been 
shown that high bleeding scores are associated with 
the presence of a mucocutaneous bleeding disorder, 
these BATs lack sensitivity, efficiency and flexibility in the 
paediatric setting. We developed a new BAT (the iCHEC 
(identifying Children with HEreditary Coagulation disorders) 
BAT) to improve on these characteristics. We aim to 
evaluate the diagnostic accuracy of the iCHEC BAT as a 
screening tool for children who are suspected for having a 
bleeding disorder.
Methods and analysis This is a prospective cohort 
study. Children (age 0–18 years) suspected for a bleeding 
disorder who present at tertiary haematology clinics, and/
or their parents/guardians, will be asked to complete 
the iCHEC BAT. Sensitivity was increased by inclusion 
of paediatric-specific bleeding symptoms and novel 
qualitative questions per bleeding symptom. Efficiency 
was improved by developing a self-administered (online) 
version of the questionnaire. Flexibility for changes in the 
bleeding phenotype of developing children was improved 
by including questions that define when the bleeding 
symptoms occurred in the past. The diagnostic accuracy 
of the specific bleeding items will be evaluated by receiver 
operator characteristic curves, using classification based 
on the results from laboratory assessment as the reference 
standard. Analysis of the discriminative power of individual 
bleeding symptoms will be assessed.
Ethics and dissemination The study has been approved 
by the medical ethics committees of all participating 
centres in the Netherlands, Canada and the UK. All 
paediatric subjects and/or their parents/guardians will 
provide written informed consent. Study results will be 
submitted for publication in peer-reviewed journals.
IntroduCtIon  
The diagnosis of an inherited bleeding 
disorder is based on the results derived from 
a patient’s bleeding history from birth, a 
family history and laboratory test results. 
Patients with mild bleeding disorders usually 
exhibit mild to moderate bleeding tenden-
cies and are therefore difficult to distinguish 
from normal subjects. Especially in children 
it is difficult for the doctor to obtain a reliable 
bleeding history, as bleeding symptoms can 
be subtle, children face fewer haemostatic 
challenges compared with adults and, for 
example, bruises in toddlers may be caused 
by normal activity. Also, some of the classic 
bleeding symptoms which are often present 
in adults with a bleeding disorder, such as 
menorrhagia and postsurgical bleeding, are 
usually not yet present in young children. 
Nevertheless, these children may have other 
bleeding symptoms that are caused by a 
bleeding disorder and require treatment. 
In order to standardise bleeding histories, 
bleeding assessment tools (BATs)1 have been 
developed. Typically, a BAT consists of ques-
tions about various bleeding symptoms, such 
as epistaxis, bleeding from minor wounds 
and bleeding after surgical procedures. 
After completion of the questionnaire, a 
strengths and limitations of this study
 ► A self-administered (online) version of the iCHEC 
BAT (identifying Children with HEreditary Coagulation 
disorders bleeding assessment tool) is available; pa-
tients and/or their parents/guardians can fill in the 
questionnaire prior to their visit to the doctor, which 
makes the assessment of the bleeding history more 
efficient.
 ► The iCHEC BAT is designed to pick up subtle cues in 
the bleeding history of a child, thereby improving the 
measurement properties of BATs for use in children.
 ► The results of this study are not generalisable to 
primary and secondary care due to a different spec-
trum of prevalence of inherited bleeding disorders 
compared with tertiary haematology centres; addi-
tional studies will be required to determine the di-
agnostic performance of the iCHEC BAT in these 
settings.
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summative bleeding score can be calculated. In 2009, the 
Pediatric Bleeding Questionnaire (PBQ) was developed 
and validated for the screening of a child for von Wille-
brand disease (vWD).2 Then, in 2010, the International 
Society on Thrombosis and Haemostasis/Scientific and 
Standardisation Committee (ISTH/SSC) developed the 
ISTH-BAT,3 which is recommended for use in haema-
tology clinics. Both the PBQ and the ISTH-BAT contain 
categories with questions for various bleeding symptoms, 
12 and 13 different bleeding symptoms, respectively, and 
one category that includes paediatric-specific bleeding 
symptoms (table 1).
It has been shown that high bleeding scores are associ-
ated with the presence of an inherited bleeding disorder.4 
However, none of the existing questionnaires/scores 
were designed with the evaluation of paediatric symptoms 
being the primary aim. The PBQ and ISTH-BAT are not 
sensitive enough to pick up subtle cues in the bleeding 
history of a child because not all the information that is 
collected about the bleeding is used for calculating the 
bleeding score and this may lead to underestimation of 
bleeding symptoms. Also, the PBQ and ISTH-BAT are 
inflexible with respect to changes in the bleeding pheno-
type of rapidly developing children. Finally, a self-ad-
ministered BAT would help to optimise the efficiency of 
bleeding history assessment. Thus, optimisation of this 
screening tool is necessary.
Therefore, we have developed a novel BAT: the iCHEC 
(identifying Children with HEreditary Coagulation 
disorders) BAT. For construction of the iCHEC BAT, the 
PBQ and ISTH-BAT were used as templates. From a thor-
ough literature review and consultation with experts, we 
have identified additional paediatric-specific bleeding 
symptoms and qualitative questions per bleeding symptom. 
These items and questions were added to the iCHEC BAT 
to increase its sensitivity for detection of subtle cues in 
the bleeding history. The PBQ and ISTH-BAT calculate a 
bleeding score based on information about the medical 
treatment of the most severe bleeding episode for specific 
bleeding symptoms. With the use of such a scoring system, 
the majority of information about the bleeding symptoms 
is not used for calculating the bleeding score and, with 
that, this potentially valuable information is not used for 
diagnostic purposes. In contrast to the scoring systems of 
the PBQ and ISTH-BAT, the iCHEC BAT scoring system 
will use all the information that has been collected from 
the completed questionnaire for calculating a bleeding 
score. For example, the iCHEC BAT includes and scores 
more detailed information about epistaxis, whereas the 
PBQ and ISTH-BAT only score information about the 
presence (no/trivial) and the treatment of the most 
severe epistaxis episode for calculating the bleeding 
score. We hypothesise that including more detailed infor-
mation about a bleeding symptom may contribute to a 
better measurement of the bleeding tendency of a child. 
The sensitivity, specificity, positive predictive value and 
negative predictive value of the PBQ for diagnosing vWD 
are 83%, 79%, 0.14 and 0.99, respectively. Although the 
Table 1 Bleeding symptoms recorded in the PBQ2 and ISTH-BAT3
Item number PBQ Item number ISTH-BAT
  1 Epistaxis 1 Epistaxis
  2 Cutaneous symptoms 2 Cutaneous bleeding
  3 Bleeding from minor wounds 3 Bleeding from minor wounds
  4 Oral cavity bleeding 4 Oral cavity bleeding
  5 Tooth extraction 5 Bleeding after tooth/teeth extraction
  6 Gastrointestinal bleeding 6 Gastrointestinal bleeding
  7 Surgery 7 Bleeding after surgery or major trauma
  8 Menorrhagia 8 Menorrhagia
  9 Postpartum haemorrhage 9 Postpartum haemorrhage
  10 Muscle haematomas 10 Muscle haematomas (spontaneous)
  11 Haemarthrosis 11 Haemarthrosis
  12 CNS bleeding 12 CNS bleeding (spontaneous)
– 13 Haematuria
  13 Other bleeding
 ► Umbilical stump bleeding.
 ► Cephalohaematoma.
 ► Bleeding at circumcision.
 ► Venipuncture bleeding.
 ► Suction bleeding.
 ► Haematuria, macroscopic.
14 Other bleeding
 ► Excessive umbilical stump bleeding.
 ► Cephalohaematoma.
 ► Bleeding at circumcision.
 ► Venipuncture bleeding.
 ► Suction bleeding.
 ► Ovulation bleeding (woman).
CNS, central nervous system; ISTH-BAT, International Society on Thrombosis and Haemostasis Bleeding Assessment Tool; PBQ, Pediatric 
Bleeding Questionnaire.
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95% CIs for specificity are reasonable (72% to 86%), they 
are quite wide for sensitivity (42% to 124%) because of 
the small number of true positives.2 Thus, we believe that 
there is room for improvement in the measurement prop-
erties of BATs for use in children. We have improved the 
flexibility of the iCHEC BAT by addressing time-depen-
dent occurrence of bleeding symptoms, which makes it 
sensitive to changes in the bleeding phenotype of a child. 
To improve efficiency, we have developed a self-adminis-
tered version of the iCHEC BAT, using careful wording 
and lay terms that are easy to understand.5 The iCHEC 
BAT was first designed in English language and has been 
translated forward into Dutch and backward to English 
to uncover mistakes in the Dutch translation. No major 
differences occurred between the original version and 
the backward translated version. From the age of 12 
years, children are allowed to fill in the questionnaire by 
themselves or with the help of their parents/guardians. 
Who completed the iCHEC BAT will be recorded. Even-
tually, we will compare the diagnostic performance of 
the iCHEC BAT with the PBQ and ISTH-BAT, which is 
possible because the iCHEC questionnaire includes the 
essential questions that are required for calculating the 
PBQ and ISTH-BAT bleeding scores.
The main goal of this study is to evaluate the diagnostic 
accuracy of the iCHEC BAT, using results from laboratory 
screening tests as reference (gold standard).
MEthods
study design
This is a prospective cohort study. The cohort will include 
200 children who are suspected for having an inherited 
bleeding disorder at tertiary haematology clinics in the 
Netherlands, Canada and the UK. Data collection will 
continue until the required number of 200 patient inclu-
sions has been reached and is expected to take approxi-
mately 1 year.
Inclusion criteria
In order to be eligible to participate in this study, a subject 
must meet the following criteria:
 ► Aged 0–18 years.
 ► Patients presenting with (1) the history, signs and 
symptoms of bleeding, and/or (2) referred for evalua-
tion of abnormal laboratory results (of blood coagula-
tion parameters), and/or (3) a positive family history 
of an inherited bleeding disorder.
Exclusion criteria
A subject who meets any of the following criteria will be 
excluded from participation in this study:
 ► Patients with a previous diagnosis of an inherited 
bleeding disorder.
 ► Patients with a known, acquired cause of bleeding, 
for example renal or liver disease, or use of medi-
cation that is known to cause an increased bleeding 
tendency.
 ► Patients and/or caregivers who are not capable to fill 
in the questionnaire, for example due to illiteracy.
sample size calculation
The prevalence of an inherited bleeding disorder in 
children presenting with bleeding symptoms at a tertiary 
clinic is approximately 20%–25%.6–8 Assuming a sensi-
tivity of 90% and specificity of 70%, a sample size of 200 
children, of whom about 45 will be affected, will yield 
95% CIs of 76% to 96% and 64% to 78% for sensitivity 
and specificity, respectively, which we consider sufficiently 
narrow.
recruitment and consent
Recruitment and consent procedures of patients at 
participating centres in the Netherlands will be as follows: 
after referral and scheduling the appointment for evalu-
ation of bleeding symptoms at the participating tertiary 
haematology clinic, subjects will be informed by email or 
by letter about this study. The secured link to the online 
version of the iCHEC BAT will be sent by email to the 
study participants. Patients and/or caregivers will fill in 
the questionnaire prior to the doctor’s appointment. 
Informed consent will be signed by one of the investiga-
tors or the treating physician when the patient visits the 
hospital with both parents/guardians of the patient, and 
the patient when 12 years or older.
Recruitment and consent procedures of patients 
at participating centres outside the Netherlands will 
proceed according to local standard procedures.
outCoMEs
The main study outcome is the diagnostic accuracy of 
the iCHEC BAT, as reflected by the area under the curve 
(AUC) of a receiver operating characteristics (ROC) 
curve using results from the laboratory assessment as 
the reference standard. The secondary outcomes are the 
influence of age, sex and type of bleeding disorder on 
the total cumulative bleeding score and the score of indi-
vidual bleeding items.
data collection
Patient characteristics
The following patient data will be collected: month and 
year of birth to calculate age; body weight and height to 
calculate body mass index; family history; medical history; 
and use of medication.
iCHEC BAT
An online version of the iCHEC BAT is available for 
patients included in the Netherlands. Patients and/or 
their parents/guardians fill in the questionnaire on a 
computer before they visit the doctor in the hospital. 
For patients included outside the Netherlands, a 
paper version of the questionnaire is available. These 
patients and/or parents/guardians fill in the question-
naire in the waiting room before they visit the doctor. 
The questions that are necessary to calculate the PBQ 
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and ISTH-BAT bleeding scores are incorporated in 
the iCHEC BAT. Bleeding scores will be calculated, 
including the total summative bleeding score, scores 
per bleeding item and scores of individual questions 
per bleeding item.
Diagnostic work-up
Participants will undergo a uniform diagnostic laboratory 
work-up for haemorrhagic disorders, which is similar to 
the standard work-up that is performed as part of routine 
care. Parameters include the following:
 ► ABO blood group.
 ► Complete blood count, including mean platelet 
volume.
 ► Activated partial thromboplastin time.
 ► Prothrombin time.
 ► Fibrinogen.
 ► Thrombin time.
 ► Platelet function analyser-100–200.
 ► Factor VIII activity (FVIII:C), FIX:C, von Willebrand 
factor antigen level (vWF:Ag) and von Willebrand 
factor activity.
 ► FVII:C, FXI:C, FXIII:C.
 ► Platelet aggregation tests (when indicated).
Additional laboratory tests
In participating centres in the Netherlands, we will 
collect extra blood for additional platelet tests in a 
subgroup of patients. This subgroup includes subjects 
with a high iCHEC bleeding score, who were not diag-
nosed with a bleeding disorder on the basis of routine 
diagnostic laboratory tests. In particular, we will perform 
additional screening tests for platelet function disor-
ders (PFDs), because, to date, it is still very difficult 
to diagnose inherited PFDs in children, for example, 
due to large amounts of blood required for analyses. 
The following tests will be performed for this specific 
subgroup of children only:
 ► Proteomic screen by mass spectrometry for PFDs.
 ► Flow cytometry approaches to assess expression levels 
of critical platelet receptors such as glycoprotein (GP)
Ib, GPV, GPIX and GPIIb-IIIa (integrin αIIbβ3).
 ► Electron microscopy.
 ► DNA isolation for genetic screening of rare PFDs.
Blood sample collection
Blood samples will be collected and analysed at the central 
laboratory of the participating centre. The amount of blood 
taken will essentially be the same as usual for the diagnostic 
work-up in the haematology clinics.
Results from the laboratory tests will be used as the refer-
ence standard. Based on these results, patients will be clas-
sified according to the presence or absence of an inherited 
bleeding disorder such as vWD, haemophilia or a PFD. 
The ‘in-house’ laboratory norm will be used to define the 
normal ranges of laboratory parameters. The diagram in 
figure 1 provides an overview of the standard diagnostic and 
study-specific procedures for eligible patients.
disease definitions 
von Willebrand disease9 10 11
 ► Type 1: partial quantitative deficiency of vWF; vWF:Ag 
at least once and/or vWF: Ristocetin (RCo) at least 
twice <50 IU/dL, vWF:RCo/vWF:Ag >0.6 and normal 
vWF multimer pattern (in the absence of blood 
type O).
 ► Type 2: qualitative vWF defects, subclassified in:
 – Type 2A: decreased vWF-dependent platelet ad-
hesion and a selective deficiency of high-mo-
lecular-weight VWF multimers; vWF:Ag and/or 
vWF:RCo <50 IU/dL on at least two occasions, 
vWF:RCo/vWF:Ag ≤0.6 and loss of high-molecu-
lar-weight multimers.
 – Type 2B: increased affinity for platelet GPIb; de-
fined similarly to type 2A with the additional re-
quirement of a hyperactive ristocetin-induced 
platelet agglutination and/or positive genetic 
testing.
 – Type 2M: decreased vWF-dependent platelet ad-
hesion without a selective deficiency of high-mo-
lecular-weight vWF multimers; vWF:Ag and/or 
vWF:RCo <50 IU/dL on at least two occasions, vW-
F:RCo/vWF:Ag ≤0.6 and normal vWF multimers.
 – Type 2N: markedly decreased binding affinity for 
FVIII; ratio of FVIII:C to vWF:Ag ≤0.6.
 ► Type 3: virtually complete deficiency of vWF; vWF:Ag 
and/or vWF:RCo <5 IU/dL.
Platelet function disorders
PFDs can be classified into inherited and acquired disorders. 
Inherited disorders can be further classified into adhesion, 
activation, secretion and aggregation defects. Acquired 
disorders can be caused by a variety of factors including 
certain drugs, uraemia and liver disease. A PFD will be diag-
nosed according to the criteria defined by the Rare Inherited 
Bleeding Disorders Committee of the Association of Haemo-
philia Centre Directors of Canada (https://www. ahcdc. ca/ 
rare- inheritedbleeding- disorders).
Classification of factor levels for coagulation factor disorders 
(tested at least twice):
1. Haemophilia A: FVIII:C<40 IU/mL.
2. Haemophilia B: FIX:C<40 IU/mL.
3. FVII deficiency: FVII <30 IU/mL.
4. FXI deficiency: FXI <60 IU/mL.
5. FXIII deficiency: FXIII <30 IU/mL.
6. Fibrinogen deficiency: fibrinogen <1.5 mg/mL.
statistical analysis
The primary aim of the study is to evaluate the diagnostic 
accuracy of the iCHEC BAT. In addition, the influence of 
age, sex and type of bleeding disorder on the total bleeding 
score and the score of individual bleeding items will be 
analysed.
We will analyse differences between affected (children 
diagnosed with an inherited bleeding disorder) and unaf-
fected children (not diagnosed with an inherited bleeding 
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disorder). Patients are classified as affected or unaffected 
based on the results of the diagnostic laboratory work-up, 
as described above. Affected and unaffected children will be 
compared with respect to the following:
 ► Total cumulative bleeding score.
 ► Scores for each individual bleeding item of the iCHEC 
BAT to determine which individual bleeding items 
are useful in distinguishing affected from unaffected 
children.
 ► Scores on individual questions per bleeding item to 
determine which questions addressing specific char-
acteristics of an individual bleeding item are useful in 
distinguishing affected from unaffected children.
Differences between the two groups of affected and 
unaffected children will be analysed statistically by the 
Mann-Whitney U test for continuous variables or χ2 test 
for categorical variables. Diagnostic performance of the 
iCHEC BAT bleeding score will be analysed by calculating 
Figure 1 Overview of the standard diagnostic (in black) and study-specific procedures (in red). Ac, activity; Ag, antigen; APTT, 
activated partial thromboplastin time; EM, electron microscopy; FACS, fluorescence-activated cell sorting; FVII, factor VII; FVIII, 
factor VIII; FIX, factor IX; FXI, factor XI; FXIII, factor XIII; iCHEC, identifying Children with HEreditary Coagulation disorders; 
ISTH-BAT, International Society on Thrombosis and Haemostasis Bleeding Assessment Tool; MS, mass spectrometry; NL, the 
Netherlands; PBQ, Pediatric Bleeding Questionnaire; PFA, platelet function analyser; PTT, partial thromboplastin time; vWF, von 
Willebrand factor.
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the AUC of the ROC curves. The AUC of the iCHEC 
BAT will be compared with the AUC of the PBQ and 
the ISTH-BAT. To address the association of bleeding 
score with age, sex and type of bleeding disorder, we will 
analyse these determinants in a multivariate model. If 
significant associations are present, we will determine the 
cut-off value to diagnose an inherited bleeding disorder 
in the relevant patient subgroups. Furthermore, we will 
compare the bleeding scores between patients who used 
the online tool versus patients who filled in the paper 
version of the iCHEC BAT to analyse the effect of admin-
istration route of the questionnaire.
Ethical considerations
Subjects can leave the study at any time for any reason if they 
wish to do so without any consequences. The investigator 
can decide to withdraw a subject from the study for urgent 
medical reasons. All participants provide written informed 
consent.
safety reporting
Adverse events are defined as any undesirable experience 
occurring to a subject during the study, whether or not 
considered related to the investigational product/trial 
procedure/the experimental intervention. All adverse 
events reported spontaneously by the subject or observed 
by the investigator or his staff will be recorded.
The iCHEC study consists of a questionnaire and a blood 
draw. In current practice, patients and/or caregivers also 
fill in a bleeding questionnaire (ISTH-BAT or PBQ) for 
diagnostic purposes. The iCHEC BAT contains questions 
that are of similar intention and will therefore not be more 
burdening to the patient. A blood draw is also part of the 
current diagnostic work-up for haemorrhagic disorders. 
Thus, this study will not change the standard diagnostic 
procedures. We do not expect that drawing an extra amount 
of (maximum 5 mL) blood in a selected group of patients in 
Dutch centres will lead to an increased risk for the patient.
study status
The first patient was enrolled on 28 March 2017. Data 
collection is expected to take approximately 1 year. Results 
will be presented at scientific meetings and published in 
peer-reviewed journals. All publications and presenta-
tions related to the study will be authorised and reviewed 
by the study investigators.
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